Catalyst Biosciences (NASDAQ:CBIO) Stock Passes Above 200 Day Moving Average of $5.60


Share on StockTwits

Shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.60 and traded as high as $6.95. Catalyst Biosciences shares last traded at $6.83, with a volume of 137,915 shares traded.

Several equities research analysts have recently issued reports on CBIO shares. Lifesci Capital reissued an “outperform” rating on shares of Catalyst Biosciences in a research report on Thursday, November 5th. Zacks Investment Research cut shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 6th. Finally, Raymond James set a $20.00 target price on shares of Catalyst Biosciences and gave the stock an “outperform” rating in a report on Tuesday, December 15th.

The company’s fifty day moving average is $6.46 and its 200 day moving average is $5.61. The firm has a market cap of $127.06 million, a price-to-earnings ratio of -1.80 and a beta of 2.07.

Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.08. The firm had revenue of $0.89 million during the quarter. As a group, equities analysts expect that Catalyst Biosciences, Inc. will post -2.48 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Nuveen Asset Management LLC acquired a new stake in Catalyst Biosciences in the second quarter valued at $453,000. Charles Schwab Investment Management Inc. acquired a new stake in Catalyst Biosciences in the second quarter valued at $255,000. Trexquant Investment LP lifted its stake in Catalyst Biosciences by 39.0% in the third quarter. Trexquant Investment LP now owns 75,686 shares of the biopharmaceutical company’s stock valued at $325,000 after acquiring an additional 21,255 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Catalyst Biosciences by 175.3% in the second quarter. Bank of New York Mellon Corp now owns 71,293 shares of the biopharmaceutical company’s stock valued at $419,000 after acquiring an additional 45,393 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its stake in Catalyst Biosciences by 49.6% in the second quarter. Engineers Gate Manager LP now owns 19,300 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 6,400 shares during the last quarter. Hedge funds and other institutional investors own 63.81% of the company’s stock.

About Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing.

Further Reading: What is a dividend reinvestment plan?

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.